Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Barbara A. Haber"'
Autor:
Regino P. Gonzalez-Peralta, Stefan Wirth, Robert H. Squires, Frauke Mutschler, Thomas Lang, Malgorzata Pawlowska, Wojciech Sluzewski, Ewa Majda-Stanislawska, Bjorn Fischler, William F. Balistreri, Maureen M. Jonas, Niviann Blondet, Philip Rosenthal, Naim Alkhouri, Rene Romero, Anjana Grandhi, Patricia Castronuovo, Luzelena Caro, Lihong Du, Daniel I.S. Rosenbloom, Barbara A. Haber
Publikováno v:
Hepatology Communications, Vol 7, Iss 3, Pp e0031-e0031 (2023)
Background:. Approximately 3.5 million children and adolescents worldwide are chronically infected with HCV. This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentrations sim
Externí odkaz:
https://doaj.org/article/0efa3d17ae6a4abb80653349bdc6fcd4
Autor:
Deanna D. Hill, Jennifer R. Kramer, Kassie R. Chaffin, T. Christopher Mast, Michael N. Robertson, Fasiha Kanwal, Barbara A. Haber
Publikováno v:
Annals of Hepatology, Vol 28, Iss 2, Pp 100899- (2023)
Introduction and Objectives: In clinical trials, patients with hepatitis C virus (HCV) genotype (GT)1a infection and baseline resistance-associated substitutions (RASs) at amino acid positions 28, 30, 31, or 93 receiving elbasvir/grazoprevir for 12 w
Externí odkaz:
https://doaj.org/article/ceeef4e9768340788243f7e373fb10ec
Autor:
Steven Flamm MD, Cheng-Yuan Peng MD, Oren Shibolet MD, Ronald Nahass MD, Peggy Hwang PhD, Eliav Barr MD, Michael N. Robertson MD, Barbara A. Haber MD
Publikováno v:
Gerontology and Geriatric Medicine, Vol 5 (2019)
Background: In elderly individuals aged ≥65 years with hepatitis C virus (HCV) infection, efficacious and safe HCV therapy is complicated by frequent comorbidities and concomitant medications. The aim of this analysis was to evaluate the efficacy a
Externí odkaz:
https://doaj.org/article/485010ee6c754ad7a4fce1c12c0cc871
Autor:
Rachel A. Kramer, Babette S. Zemel, Jessica L. Arvay-Nezu, Virginia A. Stallings, Mary B. Leonard, Barbara A. Haber
Publikováno v:
Gastroenterology Research and Practice, Vol 2009 (2009)
Objectives. To assess bone health in a cohort of nonjaundiced children with biliary atresia (BA) and the effect of growth and development on bone outcomes. Methods. Children ages one to eighteen years receiving care from Children's Hospital of Philad
Externí odkaz:
https://doaj.org/article/4b14af15db4543e78eda242ab22c2efb
Autor:
Olav Dalgard, Alain H. Litwin, Oren Shibolet, Jason Grebely, Ronald Nahass, Frederick L. Altice, Brian Conway, Edward J. Gane, Anne F. Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Barbara A. Haber, Heather Platt, Amy Puenpatom
Publikováno v:
Journal of Addictive Diseases. :1-12
Background In people with chronic hepatitis C virus (HCV) infection, viral eradication is associated with improved health-related quality of life (HRQOL). Objective To assess changes in HRQOL among participants receiving opioid agonist therapy underg
Autor:
Ajit P Limaye, Klemens Budde, Atul Humar, Julia Garcia-Diaz, Robert P Carroll, Yoshihiko Murata, Valerie L Teal, Christopher L Gilbert, Barbara A Haber
Publikováno v:
Open Forum Infectious Diseases. 9
Background VGCV is approved for prophylaxis in adult KTRs at high risk for CMV disease (donor CMV-seropositive/recipient CMV-seronegative [D+/R-]); however, its use is limited by myelosuppression. LET is non-myelotoxic, does not require dose modifica
Autor:
Jason Grebely, Gregory J. Dore, Frederick L. Altice, Brian Conway, Alain H. Litwin, Brianna L. Norton, Olav Dalgard, Edward J. Gane, Oren Shibolet, Ronald Nahass, Anne F. Luetkemeyer, Cheng-Yuan Peng, David Iser, Isaias Noel Gendrano, Michelle M. Kelly, Peggy Hwang, Ernest Asante-Appiah, Barbara A. Haber, Eliav Barr, Michael N. Robertson, Heather Platt
Publikováno v:
Annals of internal medicine. 175(9)
Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs.To evaluate the rate of HCV reinfection for 3 years after successful treatment among people receiving opioid agonist therapy
Autor:
Sanjeet Singh Dadwal, Domenico Russo, Matthias Stelljes, Michael Schmitt, Sylvain Pilorge, Valerie L. Teal, Barbara A. Haber, Charlene Bopp, Cyrus Badshah
Publikováno v:
Transplantation and Cellular Therapy. 29:S64
Autor:
Christophe, Hézode, Paul, Kwo, Jan, Sperl, Peggy, Hwang, Jianmin, Long, Rohit, Talwani, Michael N, Robertson, Barbara A, Haber
Publikováno v:
International Journal of Women's Health
Christophe Hézode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4 1Service d’Hépatologie, Hôpital Henri-Mondor, AP-HP, Université Paris-Est, INSERM U955, Créteil, France; 2Division o
Autor:
Vicky L. Ng, Lisa G. Sorensen, Estella M. Alonso, Emily M. Fredericks, Wen Ye, Jeff Moore, Saul J. Karpen, Benjamin L. Shneider, Jean P. Molleston, Jorge A. Bezerra, Karen F. Murray, Kathleen M. Loomes, Philip Rosenthal, Robert H. Squires, Kasper Wang, Ronen Arnon, Kathleen B. Schwarz, Yumirle P. Turmelle, Barbara H. Haber, Averell H. Sherker, John C. Magee, Ronald J. Sokol, Paula M. Hertel, Sanjiv Harpavat, Mary L. Brandt, Daniel H. Leung, Wikrom Karnsakul, Rebecca Torrance, Sherry Hall, Edward Doo, Jay H. Hoofnagle, Peter Whitington, Lee Bass, Alexander G. Miethke, James E. Heubi, Kenneth Setchell, Kevin E. Bove, Greg Tiao, Cara L. Mack, Michael R. Narkewicz, Amy G. Feldman, Shikha S. Sundaram, Frederick J. Suchy, Frederick M. Karrer, Mark Lovell, Johan L. Van Hove, Elizabeth B. Rand, James E. Squires, Veena L. Venkat, Rakesh Sindhi, Sarangarajan Ranganathan, Laura Bull, Jeffrey Teckman, Molly Bozic, Girish Subbarao, Simon Horslen, Evelyn Hsu, Laura Finn, Patrick Healey, Rohit Kohli, Danny Thomas, Nisreen Soufi, Sonia Michail, Matt Clifton, Nitika Gupta, Rene Romero, Miriam Vos, Shelley Caltharp, Binita M. Kamath, Simon C. Ling, Anna Gold, Annie Fecteau, Stephen L. Guthery, Kyle Jensen, Rebecka Meyers, Amy Lowichik, Linda Book, Robert M. Merion, Cathie Spino, Karen Jones
Publikováno v:
The Journal of pediatrics. 196
To assess neurodevelopmental outcomes among participants with biliary atresia with their native liver at ages 12 months (group 1) and 24 months (group 2), and to evaluate variables predictive of neurodevelopmental impairment.Participants enrolled in